<DOC>
	<DOCNO>NCT02116140</DOCNO>
	<brief_summary>Obstructive sleep apnea ( OSA ) , central sleep apnea ( CSA ) heart failure ( HF ) state metabolic demand sympathetic nervous system ( SNS ) activation . In patient sleep apnea HF , continuous positive airway pressure ( CPAP ) initially may reduce left ventricular ( LV ) stroke volume ( SV ) subsequently improve LV function . This may relate early beneficial effect myocardial energetics early reduction metabolic demand subsequently lead improved efficiency LV contraction . However , clear whether long-term adaptive servo-ventilation ( ASV ) favorably affect cardiac energetics . Any benefit may also relate reduce sympathetic nervous system ( SNS ) activation . However effect myocardial SNS function also well study . In pilot study demonstrate early ( 6 week ) beneficial effect CPAP patient OSA HF . The current proposal ( AMEND ) unique substudy recently fund ADVENT-HF trial ( Adaptive Servo Ventilation Therapy Sleep Apnea HeartFailure ) ( NCT01128816 ; CIHR ; D. Bradley , PI ) . We propose evaluate long-term ( 6 month ) effect ASV daytime 1 ) oxidative metabolism ; 2 ) work metabolic index ( WMI ) estimate mechanical efficiency ; 3 ) myocardial sympathetic nerve ( SN ) pre-synaptic function ; 4 ) heart rate ( HR ) variability patient HF coexist OSA CSA . In conjunction echocardiographic measure LV stroke work , positron emission tomography ( PET ) derive [ 11C ] acetate kinetics use measure oxidative metabolism , determine WMI . [ 11C ] hydroxyephedrine ( HED ) retention use measure cardiac SN pre-synaptic function . Primary Hypotheses : In patient chronic stable HF CSA OSA without excessive daytime sleepiness ( EDS ) , long-term ( 6-month ) ASV therapy yield : 1 . Beneficial effect daytime myocardial metabolism lead reduction rate oxidative metabolism measure [ 11C ] acetate kinetics use PET imaging ; 2 . Improvement energy transduction oxidative metabolism stroke work measure increase daytime work-metabolic index .</brief_summary>
	<brief_title>ASV Effects Myocardial Energetics Sympathetic Nerve Function Heart Failure Sleep Apnea .</brief_title>
	<detailed_description>DEFINITIONS Obstructive sleep apnea ( OSA ) characterize : episode partial complete pharyngeal collapse lead obstructive hypopnea apnea sleep . OSA often coexist HF . Central sleep apnea ( CSA ) characterize : reduction central respiratory drive sleep lead episodes partial complete cessation airflow . CSA often co-exists HF . Continuous positive airway pressure ( CPAP ) deliver air nasal oral interface preserve upper airway patency . It treatment symptomatic OSA patient CSA . Adaptive Servoventilation ( ASV ) effective alleviate OSA CSA . It provide expiratory positive pressure alleviate OSA , inspiratory positive airway pressure eliminate CSA . Oxidative metabolism : utilization substrates via tricarboxylic acid cycle Adenosine triphosphate ( ATP ) production ; link myocardial oxygen consumption measure [ 11C ] acetate PET . The work-metabolic index ( WMI ) external work ( minute-work ) leave ventricle correct rate oxidative metabolism estimate mechanical efficiency . Myocardial sympathetic neuron ( SN ) presynaptic function measure uptake storage neuronal catecholamine heart measure [ 11C ] hydroxyephedrine ( HED ) PET .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Sleep Apnea , Central</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>This study ( AMEND ) single centre substudy ADVENTHF trial ( NCT01128816 ) . ADVENTHF RCT test effect ASV morbidity mortality patient HF OSA CSA . The AMEND substudy clinical physiologic proposal design determine effect longterm ( 6 month ) ASV cardiac energetics SN function patient chronic stable HF sleep apnea extend previous evaluation shortterm CPAP patient OSA HF 1 . American Heart Association ( AHA ) Stages B , C D heart failure due ischemic , idiopathic hypertensive cause ; 2. systolic dysfunction , ejection fraction ( EF ) ≤45 % echocardiography 3. optimal medical therapy conform AHA guideline ( proposal , stable therapy &gt; 4 week ) 4. sleep apnea Apnea/hypopnea Index ≥15 , divide OSA ( &gt; 50 % event obstructive ) , CSA ( &gt; 50 % event central nature ) patient OSA , Epworth Sleepiness Scale score &gt; 10 mild daytime sleepiness ( International Classification Sleep Disorders 5. age &gt; 18 year ; 6. willingness receive ASV therapy 7. informed consent 1 . Myocardial infarction , cardiac surgery angioplasty within 3 month prior enrollment , 2. list heart transplantation , 3 . HF due primary valvular heart disease , 4. pregnancy 5. current use ASV CPAP . 6. await revascularization ; 7. previous cardiac transplant ; 8. life expectancy le 6 month due comorbidity ; 9. large transmural scar define previous perfusion imaging ( severe rest perfusion defect ( &lt; 50 % uptake ) occupy &gt; 25 % LV ) ; 10. concomitant treatment use : tricyclic antidepressant , cocaine drug may alter catecholamine uptake . For heart rate variability ( HRV ) analysis additional exclusion include : ) permanent pacemaker ; b ) atrial fibrillation ; c ) significant ventricular arrhythmia sinus node dysfunction ; patient may exclude HRV analysis still eligible substudy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>positron emission tomography</keyword>
	<keyword>[ 11C ] hydroxyephedrine ( HED )</keyword>
	<keyword>[ 11C ] acetate</keyword>
	<keyword>Adaptive Servoventilation ( ASV )</keyword>
	<keyword>Myocardial Energetics</keyword>
	<keyword>work-metabolic index ( WMI )</keyword>
	<keyword>Myocardial sympathetic neuron ( SN ) presynaptic function continuous positive airway pressure</keyword>
	<keyword>heart rate variability</keyword>
	<keyword>overnight polysomnogram</keyword>
	<keyword>Plasma Norepinephrine</keyword>
	<keyword>Urine Normetanephrine</keyword>
	<keyword>Quality Life</keyword>
</DOC>